Immune Thrombocytopenia
We recommend
How do patients perceive the treatment of ITP with romiplostim?
Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.
Central European Expert Consensus on the Treatment of ITP in Adult Patients
In a recently published consensus, experts from Central Europe evaluate the current treatment…
ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in…
Articles on this topic
Treatment of Immune Thrombocytopenia: Choice of TPO Mimetics in Clinical Practice
Real-world data show that the administration of thrombopoietin receptor agonists in immune…
Current ASH Guidelines for Management of ITP 2019 − Recommendations for Newly Diagnosed ITP in Adults
The American Society of Hematology (ASH) published current guidelines for immune…
Subscribe
E-courses on this topic
Conferences news
Go to records
Go to records
Most read on this topic
- COVID-19 and Immune Thrombocytopenic Purpura − Spanish Experience Suggests Surprising Connections
- Idiopathic Thrombocytopenic Purpura with SARS-CoV-2 Infection
- Thrombocytopenia Following mRNA Vaccination Against SARS-CoV-2
- Fatigue as a Significant Symptom of Immune Thrombocytopenia from the Patients' Perspective
- Summary of Recommendations for the Treatment of Immune Thrombocytopenia in Pregnancy
- Current ASH Guidelines on ITP Management 2019 – Recommendations for Newly Diagnosed ITP in Children
Journal on this topic
Related topic